samedan logo

 
 
spacer
home > pmps > autumn 2003 > generics boards surfing the new wave in contract manufacturing services
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Generics Boards Surfing the New Wave in Contract Manufacturing Services

With the rapidly rising tide in sales of unbranded medicines, are the holders of expiring patents for branded products about to find themselves stranded on the rocks or simply getting wet feet?

Recent developments at the WTO and changes in Europe's pharmaceutical legislation could drive suppliers of generics to outsource development and production to countries like Portugal, where they can take the necessary steps before the tide turns for their branded or innovator competition.

With about 35 per cent of pharma's lucrative blockbusters coming off patent by 2007, the rising tide of generics will experience a big surge driving the managerial boards of generics suppliers to get to market as early as possible, preferably as soon as the bell-buoy rings 'time up'.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Patricia Lobo, Editor of PMPS and Associate Director at Technomark Consulting Services Limited

Patricia Lobo PhD, Associate Director and Senior Consultant at Technomark Consulting Services Ltd, is the Editor of Pharmaceutical Manufacturing and Packing Sourcer (PMPS) published by Samedan Ltd. Patricia has worked for over 25 years in the pharmaceutical industry in quality control, clinical research, marketing and business development. Since she joined Technomark in 1992, Patricia has developed considerable expertise and a first class reputation in the core business of outsourcing clinical trials, and in contract manufacturing and packaging, providing in-depth market reports and strategic planning advice to a wide range of pharma and biotech companies.

spacer
Dr Patricia Lobo
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Signant Health Debuts Standardized Electronic Seizure Diary Developed in Collaboration with The Epilepsy Study Consortium

PHILADELPHIA, PA January 17, 2023 Signant Health, the leader in evidence generation for modern clinical trials, introduced today a novel electronic diary (eDiary) data capture solution designed to simplify the experience for patients and research sites participating in epilepsy trials while ensuring robust outcome assessment data to support trial endpoints. Developed in collaboration with The Epilepsy Study Consortium (TESC), the new patient-reported outcome measure offers clinical research sponsors and organizations a standardized solution to capture common seizure-data elements with high-quality data.
More info >>

White Papers

Accelerating the Time from DNA to Material

Merck

Cell line development is a critical step in upstream process development for monoclonal antibodies (mAbs). Unfortunately, the search for the bestproducing clone can be labor- and resource-intensive and is often compared with looking for a needle in a haystack. Cells must first be engineered to produce the biologic of interest and the cell line generated from a high producing clone must deliver a sufficiently high titer to support clinical studies, and ultimately commercialization of the therapeutic.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement